Budesonide and Albuterol Oral Inhalation
Budesonide and albuterol oral inhalation (Airsupra) is a rescue inhaler for adults with asthma, used as needed to treat or prevent airway tightening and to lower the risk of asthma flare-ups.
🧬 Where this information comes from
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Airsupra is a newer as-needed rescue inhaler for adults with asthma, on the U.S. market since about 2023 and not available as a generic. It pairs albuterol (relaxes airway muscles to open them fast) with budesonide (a steroid that calms airway inflammation), so each use relieves or prevents tightening and lowers flare-up risk. It is generally well tolerated; headache, cough, a hoarse voice and oral thrush (a mouth yeast infection) are the usual complaints, and rinsing with water and spitting after each use helps prevent thrush. Needing it more often than usual, or getting less relief, means your asthma is worsening and your prescriber should hear about it.
Clinical pearls
- Stay under the daily maximum on the label, because too much albuterol can cause serious, even fatal, heart effects.
- Do not stack it with another albuterol rescue inhaler unless your prescriber planned both, since doubling up risks an overdose.
- Beta blockers can blunt Airsupra and may trigger severe airway spasm, so mention it before starting one for blood pressure or heart conditions.
- Ketoconazole, itraconazole, ritonavir and clarithromycin can raise budesonide levels, so flag Airsupra whenever one is prescribed.
Patient Information Guide A plain-language walkthrough of Budesonide and Albuterol Oral Inhalation, written from its FDA label.
What Budesonide and Albuterol Oral Inhalation Is Used For
▾
Budesonide and albuterol oral inhalation is used for asthma. The supported product is Airsupra:
- Airsupra is used as needed to treat or prevent bronchoconstriction (airway tightening) in adults 18 and older with asthma.
- Airsupra is also used to reduce the risk of asthma exacerbations (flare-ups) in adults 18 and older.
How Budesonide and Albuterol Oral Inhalation Works
▾
Airsupra combines two medicines. Albuterol is a short-acting beta2-agonist. It activates beta2 receptors on airway muscle, which relaxes the muscle from the large airways down to the smallest ones and opens them.
Budesonide is a corticosteroid that works against inflammation, which plays an important role in asthma. When inhaled, it acts mostly directly in the airways. The exact way corticosteroids calm asthma inflammation is not fully known.
Budesonide and Albuterol Oral Inhalation Dosage
▾
Airsupra is inhaled through the mouth as needed for asthma symptoms.
- Each dose is 2 puffs. Do not take more than 6 doses (12 puffs) in 24 hours.
- Prime before first use. Re-prime if unused for more than 7 days, dropped or cleaned.
- The dose counter shows puffs left. Discard the inhaler at zero.
- Rinse your mouth with water afterward and spit it out.
Follow your prescriber's directions and the product label.
Dosing details from the FDA-approved label
From the Budesonide and Albuterol Oral Inhalation prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- As needed treatment of asthma symptoms (recommended dosage)
- Albuterol 180 mcg and budesonide 160 mcg (administered as 2 actuations of AIRSUPRA [albuterol/budesonide 90 mcg/80 mcg]) as needed for asthma symptoms by oral inhalation
- Maximum: Do not take more than 6 doses (12 inhalations) in a 24-hour period
- Prime before first use with 4 sprays into the air away from the face, shaking well before each spray; re-prime with 2 sprays if not used for more than 7 days, dropped, or after cleaning; discard when the dose indicator pointer reaches zero
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION • Recommended Dosage: AIRSUPRA 180 mcg/160 mcg (administered as 2 actuations of albuterol/budesonide 90 mcg/80 mcg) by oral inhalation as needed for asthma symptoms. ( 2.1 ) • Do not take more than 6 doses (12 inhalations) in a 24-hour period. ( 2.1 ) • Prime inhaler prior to first use. Re-prime when inhaler has not been used for more than 7 days, is dropped, or after cleaning. ( 2.2 ) • Discard when the dose counter displays 0. ( 2.3 ) 2.1 Recommended Dosage and Administration The recommended dosage of AIRSUPRA is albuterol 180 mcg and budesonide 160 mcg (administered as 2 actuations of AIRSUPRA [albuterol/budesonide 90 mcg/80 mcg]) as needed for asthma symptoms by oral inhalation. Do not take more than 6 doses (12 inhalations) in a 24-hour period [see Warnings and Precautions (5.4) ] . 2.2 Priming Before Use • Priming AIRSUPRA is essential to ensure appropriate drug content in each actuation. Prime AIRSUPRA before using for the first time. To prime AIRSUPRA, release 4 sprays into the air away from the face, shaking well before each spray. • AIRSUPRA must be re-primed when the inhaler has not been used for more than 7 days, is dropped, or after cleaning. To re-prime AIRSUPRA, release 2 sprays into the air away from the face, shaking well before each spray. 2.3 Dose Counter The canister has an attached dose indicator (also known as puff indicator) which indicates how many inhalations (puffs) remain. The dose indicator pointer will move after every actuation. The pointer will show the number of inhalations remaining in the canister. When nearing the end of the usable inhalations, the color behind the number in the dose indicator display window changes to yellow. AIRSUPRA should be discarded when the pointer reaches zero.
Read the full Dosage and Administration section on DailyMed →
Budesonide and Albuterol Oral Inhalation Side Effects
▾
The most common side effects in studies were:
Common side effects
- Headache
- Oral thrush (a yeast infection in the mouth)
- Cough
- Hoarse or changed voice (dysphonia)
- Hoarseness or voice changes
When to get medical help
- Get help right away if your breathing suddenly gets worse after a dose (paradoxical bronchospasm). Stop using it.
- Get emergency help for signs of an allergic reaction, such as swelling of the face, lips or throat, hives, rash or trouble breathing.
- Call your doctor if symptoms continue after using it, or you need more doses than usual. Your asthma may be getting worse.
- Call your doctor if you have a fast or pounding heartbeat, chest pain, or a big rise in blood pressure.
- Call your doctor about white patches or soreness in your mouth or throat.
- Call your doctor if you develop vision changes or eye symptoms.
- Tell your doctor if you are exposed to chickenpox or measles, or develop signs of infection.
Get help right away for sudden worsening breathing after a dose, allergic reactions, or heart-related symptoms like chest pain or a racing heartbeat. Tell your doctor about mouth sores or white patches, or eye symptoms.
Budesonide and Albuterol Oral Inhalation Warnings and Precautions
▾
- Too much can be dangerous. Serious heart effects and deaths have been reported with excessive use of inhaled drugs like albuterol. Stay within the daily maximum.
- Worsening asthma: Needing more doses than usual, or ongoing symptoms, means your treatment needs review.
- Paradoxical bronchospasm: Airways may tighten after a dose, often with the first use of a new inhaler. Stop and seek help.
- Heart effects: Heart rate and blood pressure may rise. Use caution with heart disease.
- Allergic reactions, including anaphylaxis, can occur.
- Low potassium may occur, usually briefly.
- Corticosteroid effects: mouth thrush, worsened infections (chickenpox and measles can be serious), adrenal suppression, lower bone density, glaucoma and cataracts.
Budesonide and Albuterol Oral Inhalation Interactions
▾
No formal interaction studies have been done, but the label advises care with:
- Beta blockers: can block albuterol and cause severe bronchospasm.
- Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, itraconazole and others): raise budesonide exposure.
- Other short-acting beta agonists: risk of overdose.
- Non-potassium-sparing diuretics: can worsen low potassium or ECG changes.
- Digoxin: levels may fall.
- MAOIs and tricyclic antidepressants: can increase heart effects of albuterol.
Interactions listed in the FDA-approved label
From the Budesonide and Albuterol Oral Inhalation prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin): May inhibit the metabolism of, and increase the systemic exposure to, budesonide, and may cause systemic corticosteroid effects. Use with caution.
- Other short-acting bronchodilators (beta-agonists): AIRSUPRA contains the short-acting beta-agonist albuterol, so additional beta-agonists risk beta-agonist overdose. Use additional beta-agonists judiciously.
- Beta-blockers: May block the pulmonary effect of albuterol, decrease effectiveness of AIRSUPRA, and produce severe bronchospasm in patients with asthma. Patients with asthma should not normally be treated with beta-blockers; when there are no acceptable alternatives, consider cardioselective beta-blockers and administer with caution.
- Diuretics (non-potassium-sparing diuretics such as loop or thiazide diuretics): ECG changes and/or hypokalemia can be acutely worsened by beta-agonists, especially when the recommended beta-agonist dose is exceeded. Caution is advised; consider monitoring potassium levels.
- Digoxin: Mean decreases of 16% and 22% in serum digoxin levels were seen after single-dose intravenous and oral albuterol, respectively, in normal volunteers; clinical significance is unclear. Carefully evaluate serum digoxin levels in patients receiving digoxin and AIRSUPRA.
- Monoamine oxidase inhibitors and tricyclic antidepressants: The action of albuterol on the cardiovascular system may be potentiated, including within 2 weeks of discontinuing such agents. Administer AIRSUPRA with extreme caution.
Read the label’s full interactions text
7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. • Strong cytochrome P450 3A4 inhibitors (e.g. ritonavir): Use with caution. May cause systemic corticosteroid effects. ( 7.1 ) • Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. ( 7.2 ) • Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. ( 7.3 ) • Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. ( 7.4 ) • Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. ( 7.5 ) • Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. ( 7.6 ) 7.1 Inhibitors of Cytochrome P450 3A4 The main route of metabolism of corticosteroids, including budesonide, a component of AIRSUPRA, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. Concomitant administration of a CYP3A4 inhibitor may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the co-administration of AIRSUPRA with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.11) ] . 7.2 Use with Other Short-Acting Bronchodilators AIRSUPRA contains the short-acting beta-agonist, albuterol. Therefore, concomitant use of additional beta-agonists with AIRSUPRA should be used judiciously to prevent beta-agonist overdose.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before Taking Budesonide and Albuterol Oral Inhalation
▾
- Do not use if allergic to albuterol, budesonide or any ingredient.
- Use caution with heart disease, irregular heartbeat or high blood pressure.
- Use caution with seizure disorders, hyperthyroidism, diabetes or ketoacidosis.
- Use caution with tuberculosis, untreated infections or ocular herpes simplex.
- People with risk factors for weak bones should be monitored.
- Severe liver disease can raise budesonide levels, so monitoring is advised.
- Not established for children. It is indicated for adults 18 and older.
- Pregnancy: discuss with your doctor. Uncontrolled asthma itself carries risks in pregnancy. Use during labor only if benefits clearly outweigh risks.
- Breastfeeding: budesonide is present in breast milk.
Budesonide and Albuterol Oral Inhalation Overdose
▾
Too much albuterol can cause seizures, chest pain, high or low blood pressure, a very fast or irregular heartbeat, tremor, nervousness, muscle cramps, nausea and low potassium. Cardiac arrest and death have been associated with abuse. Treatment is to stop Airsupra and treat symptoms. Excessive budesonide over a long time can cause systemic corticosteroid effects.
What Budesonide and Albuterol Oral Inhalation Does in the Body
▾
Albuterol relaxes airway muscle and can raise pulse rate and blood pressure in some people. Budesonide acts mainly locally in the airways and lowers airway reactivity. Like other inhaled corticosteroids, Airsupra may affect the HPA axis (the body's cortisol-regulating system), especially at high doses for long periods.
How Your Body Processes Budesonide and Albuterol Oral Inhalation
▾
After inhalation, budesonide levels peak in about 20 minutes (median) and albuterol in about 1 hour. Average half-lives are about 4.1 hours for budesonide and 7.1 hours for albuterol. Budesonide is broken down extensively in the liver by CYP3A4, and its metabolites are mostly inactive. Albuterol is cleared mainly by the kidneys, and kidney disease can reduce albuterol clearance.
How to Store Budesonide and Albuterol Oral Inhalation
▾
Store at controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) . Keep in a dry place away from heat and sunlight. Keep out of reach of children.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Budesonide and Albuterol Oral Inhalation: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Budesonide and Albuterol Oral Inhalation — the kind of thing our pharmacy team would talk through with you at the counter.
What is Airsupra for?
▾
How do I use it?
▾
What side effects should I expect?
▾
When should I call my doctor?
▾
Can I take it with my other medicines?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Is Budesonide and Albuterol Oral Inhalation available over the counter?
▾
When was Budesonide and Albuterol Oral Inhalation first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More About Budesonide and Albuterol Oral Inhalation on HelloPharmacist
Budesonide and Albuterol Oral Inhalation Forms and Strengths (How It Comes)
Budesonide and Albuterol Oral Inhalation is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Budesonide and Albuterol Oral Inhalation inactive ingredients by manufacturer.
Inhaler
How this form is used
- Airsupra is used as needed to treat or prevent bronchoconstriction in adults 18 and older with asthma.
- Airsupra is also used to reduce the risk of asthma exacerbations in adults 18 and older.
- Airsupra is taken by oral inhalation as needed for asthma symptoms, 2 puffs per dose, with no more than 6 doses (12 puffs) in 24 hours.
- Prime Airsupra before first use, and re-prime it if unused for more than 7 days, dropped, or after cleaning.
- Airsupra has a dose counter. Discard the inhaler when it reads 0.
- Rinse your mouth with water after using Airsupra and spit it out.
Budesonide and Albuterol Oral Inhalation on the U.S. Market: Products, Makers and Brands
How Budesonide and Albuterol Oral Inhalation appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 1 Budesonide and Albuterol Oral Inhalation product record with the FDA, mostly as inhaler; the earliest marketing or approval year on record is 2023. Brand names on the directory include Airsupra; the rest are generics.
How Widely Budesonide and Albuterol Oral Inhalation Is Used (Medicaid Data)
A general measure of how commonly Budesonide and Albuterol Oral Inhalation is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Budesonide and Albuterol Oral Inhalation is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Budesonide and Albuterol Oral Inhalation prescribed? Of the 1,601 medications we measure, Budesonide and Albuterol Oral Inhalation ranks #544 by Medicaid prescriptions — more than 66% of them.
Utilization by Budesonide and Albuterol Oral Inhalation product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
120 ACTUAT albuterol 0.09 MG/ACTUAT / budesonide 0.08 MG/ACTUAT Metered Dose Inhaler
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2665906
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Budesonide and Albuterol Oral Inhalation, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 1 listed Budesonide and Albuterol Oral Inhalation NDCs with Medicaid activity.
Compare Budesonide and Albuterol Oral Inhalation Products
A representative set of FDA-listed product records for Budesonide and Albuterol Oral Inhalation — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Inhaler | ||||
| ALBUTEROL SULFATE 90 mcg/1; BUDESONIDE 80 mcg | Respiratory (inhalation) | AstraZeneca Pharmaceuticals LP | NDA | View NDC → |
Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Budesonide and Albuterol Oral Inhalation NDCs →
Budesonide and Albuterol Oral Inhalation Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Budesonide and Albuterol Oral Inhalation — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Budesonide and Albuterol Oral Inhalation in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Budesonide and Albuterol Oral Inhalation FDA Approval History
How Budesonide and Albuterol Oral Inhalation went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Budesonide and Albuterol Oral Inhalation Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Budesonide and Albuterol recalls since July 2021.
✅No Budesonide and Albuterol recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Oct 8, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one exact multiple-ingredient concept (MIN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). A product with a different ingredient combination belongs on a different page.
RxCUI 2632021 1 dose form · 2 strengths
-
Dose form (SCDF) Metered Dose Inhaler RxCUI 2665905In current FDA listingsClinical drug / strength (SCD) 28 ACTUAT albuterol 0.09 MG/ACTUAT / budesonide 0.08 MG/ACTUATRxCUI 2678391120 ACTUAT albuterol 0.09 MG/ACTUAT / budesonide 0.08 MG/ACTUATRxCUI 2665906
Look up RxCUI 2632021 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Budesonide and Albuterol Oral Inhalation Supply and Shortage Status
Whether Budesonide and Albuterol Oral Inhalation is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Budesonide and Albuterol Oral Inhalation Costs Pharmacies (NADAC Benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Aerosol, Metered · Respiratory (inhalation) | 90; 80 mcg/1; mcg | $45.03 per gram | NDC details & price history |
| Aerosol, Metered · Respiratory (inhalation) | ALBUTEROL SULFATE 90 mcg/1; BUDESONIDE 80 mcg | $45.03 per gram | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Budesonide and Albuterol Oral Inhalation Brand Names
Budesonide and Albuterol Oral Inhalation is sold under one brand name in the FDA directory — Airsupra. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who Makes Budesonide and Albuterol Oral Inhalation: Manufacturers and Labelers
One company lists Budesonide and Albuterol Oral Inhalation products with the FDA. By number of product records, the largest are AstraZeneca Pharmaceuticals LP. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Budesonide and Albuterol Oral Inhalation Drug Class (RxNorm)
Budesonide and Albuterol Oral Inhalation belongs to the Corticosteroid class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for This Budesonide and Albuterol Oral Inhalation Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. AstraZeneca Pharmaceuticals LP is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →